New treatments for chronic obstructive pulmonary disease

Annali dell'Istituto Superiore di Sanita

Volumn 39, Issue 4, 2003, Pages 573-582

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti inflammatory; Elastase; Nuclear factor B; Phosphodiesterase 4 inhibitors; TNF

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ELASTASE; ELASTASE INHIBITOR; GLUTATHIONE DERIVATIVE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIPOXYGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEW DRUG; NITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LUNG EMPHYSEMA; LUNG INJURY; LUNG PARENCHYMA; NAUSEA; NONHUMAN; OXIDATIVE STRESS; REVIEW; SMALL AIRWAY DISEASE; SMOKING CESSATION;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HUMANS; INFLAMMATION MEDIATORS; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 1842480947     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1S-4S.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3.
3. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999;340:1881-7.
4. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
5. Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Found Symp 2001; 234:4-19.
6. Barnes PJ. New concepts in COPD. Ann Rev Med 2003;54:113-29.
7. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117:10S-4S.
8. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
9. Barnes PJ. New treatments for chronic obstructive pulmonary disease. Curr Opin Pharmacol 2001;1:217-22.
10. Barnes PJ. New treatments for COPD. Nature Rev Drug Discov 2002;1:437-45.
11. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
12. Shapiro SD. Animal models for COPD. Chest 2000;117:223S-7S.
13. Dawkins PA, Stockley RA. Animal models of chronic obstructive pulmonary disease. Thorax 2001;56:972-977.
14. Hansel TT, Barnes PJ. New drugs for asthma and COPD. Basel: Karger, 2001.
15. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000;321:355-8.
16. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
17. Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, Nides MA et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet 2001;357:1571-5.
18. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane Review). Cochrane Database Syst Rev 2000 4:CD000031.
19. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000;59:1007-24.
20. Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
21. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:63S-6S.
22. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
23. Casaburi R, Briggs DDJ, Donohue JF, Serby CW, Menjoge SS, Witek TJJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial [In Process Citation]. Chest 2000;118:1294-302.
24. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55:289-94.
25. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
26. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
27. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, Van der Mark TW, Koeter GH et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55:12-8.
28. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893-8.
29. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192:421-32.
30. Silbaugh SA, Stengel PW, Cockerham SL, Froelich LL, Bendele AM, Spaethe SM et al. Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmied Arch Pharmacol 2000; 361:397-404.
31. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-80.
32. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
33. Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 1999;66:401-10.
34. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-242.
35. Traves SL, Culpitt S, Russell REK, Barnes PJ, Donnelly LE. Elevated levels of the chemokines GRO-α and MCP-1 in sputum samples from COPD patients. Thorax 2002;57:590-5.
36. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-8.
37. Hay DWP, Sarau HM. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol 2001;1:242-7.
38. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619-26.
39. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633-7.
40. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
41. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
42. Barlaam B, Bird TG, Lambert-Van DB, Campbell D, Foster SJ, Maciewicz R. New alpha-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors. J Med Chem 1999;42:4890-8.
43. Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG et al. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 2001;44:4252-67.
44. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
45. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:369-73.
46. Macnee W. Oxidants/antioxidants and COPD. Chest 2000; 117:303S-17S.
47. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22:209-21.
48. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4.
49. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001;53:135-59.
50. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Resp Crit Care Med 2000;160:701-6.
51. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220.
52. Erin EM, Hansel TT, Kharitonov SA, Donnelly LE, Currie MG, Manning PT et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide. Am J Respir Crit Care Med 2002;165:A187.
53. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
54. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
55. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen T. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ 2000;320:1297-303.
56. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
57. Barnes PJ. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2000;161:342-4.
58. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
59. Culpitt SV, Nightingale JA, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
60. Nightingale JA, Rogers DF, Chung KF, Barnes PJ. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med 2000;161:479-86.
61. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8.
62. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1100-2.
63. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000;47:127-62.
64. Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14:157-64.
65. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
66. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-70.
67. Edelson J, Compton CH, Nieman R, Robinson CB, Amit O, Bagchi I. Cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6-month trial. Am J Respir Crit Care Med 2001;163: A771.
68. Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J Clin Pharmacol 2002;42:297-303.
69. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature 2000;406:367-8.
70. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IKK activation and IκBa degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem 1999;274:19965-72.
71. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000;105:769-75.
72. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, Macnee W et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-7.
73. Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999;14:309-14.
74. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-82.
75. Carter AB, Monick MM, Hunninghake GW. Both erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 1999;20:751-8.
76. Meja KK, Seldon PM, Nasuhara Y, Ito K, Barnes PJ, Lindsay MA et al. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-κB-independent mechanism. Br J Pharmacol 2000;131:1143-53.
77. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185-201.
78. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L895-902.
79. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira dSA, Stanford WL, Bolon B et al. Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287:1040-6.
80. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160:S49-S52.
81. Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999;20:1100-2.
82. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991;177:814-20.
83. Fujie K, Shinguh Y, Yamazaki A, Hatanaka H, Okamoto M, Okuhara M. Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. Inflamm Res 1999;48:160-7.
84. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000;192:789-800.
85. Leung-Toung R, Li W, Tam TF, Karimian K. Thiol-dependent enzymes and their inhibitors: a review. Curr Med Chem 2002; 9:979-1002.
86. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-9.
87. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997;3:675-7.
88. Belloni PN, Garvin L, Mao CP, Bailey-Healy I, Leaffer D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000;117:235S-41S.
89. Mao JT, Goldin JG, Dermand J, Ibrahim G, Brown MS, Emerick A et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 2002;165:718-23.
90. Otto WR. Lung epithelial stem cells. J Pathol 2002;197:527-35.
91. Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp 2002;248:237-249.
92. Smith KR. Inaugural article: national burden of disease in India from indoor air pollution. Proc Natl Acad Sci USA 2000; 97:13286-93.
93. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999;54:245-52.
94. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-6.
95. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-772.
96. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002;23:232-7.